Get the Stockscreener App
6.63
9.59%
0.58
After Hours:
6.64
0.010
+0.15%
Emergent Biosolutions Inc stock is traded at $6.63, with a volume of 914.65K.
It is up +9.59% in the last 24 hours and up +38.41% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$6.05
Open:
$6.17
24h Volume:
914.65K
Relative Volume:
0.75
Market Cap:
$343.04M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.4492
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+4.91%
1M Performance:
+38.41%
6M Performance:
-26.42%
1Y Performance:
+5.91%
1-Day Range:
$6.155
$6.67
1-Week Range:
$6.01
$6.67
52-Week Range:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
6.63 | 343.04M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
170.16 | 75.08B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
11.07 | 51.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 46.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.77 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
325.82 | 14.38B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Emergent BioSolutions (EBS) Partners with Foundation for Opioid Awareness | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's Nat - GuruFocus
Breaking: Dramatic 34% Drop in US Opioid Deaths as Emergent Expands Life-Saving Naloxone Access - Stock Titan
Vaccine Contract Manufacturing Market Set to Witness - openPR.com
Biodefense Market Set to Witness Significant GrowthEmergent BioSolutions Inc., SIGA Technologies - openPR.com
Bank of America Corp DE Boosts Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Northern Trust Corp Acquires 3,692 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions discloses CEO stock purchase - MSN
Emergent Biosolutions Settlement Receives Preliminary Approval - TipRanks
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions - Yahoo Finance
Q1 EPS Forecast for Emergent BioSolutions Lowered by Analyst - Defense World
Emergent BioSolutions (EBS) Shares Surge 9.7% Following Positive Developments | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) CEO Increases Stake with $350,000 Sh - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 13% | EBS Stock Ne - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 14% | EBS Stock Ne - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 14% | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 13% | EBS Stock News - GuruFocus
Emergent BioSolutions stock up on insider purchase (EBS:NYSE) - Seeking Alpha
Insider Buying: Joseph Papa Acquires 60,000 Shares of Emergent B - GuruFocus
Insider Buying: Joseph Papa Acquires 60,000 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus
Emergent BioSolutions to Participate in Upcoming Investor Conferences | EBS Stock News - GuruFocus
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent BioSolutions Lines Up 4 Major Wall Street Conferences: RBC, Goldman Sachs, Jefferies Featured - Stock Titan
Wells Fargo & Company MN Sells 11,665 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st
Emergent BioSolutions (EBS) Q1 2025 Earnings Highlight Turnaroun - GuruFocus
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress - MSN
Emergent Biosolutions: Q1 Earnings Snapshot - New Haven Register
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... - Yahoo
Emergent BioSolutions Reports First Quarter 2025 Financial Results - The Manila Times
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid Revenue Challenges - GuruFocus
Earnings call transcript: Emergent BioSolutions Q1 2025 sees 656% net income rise - Investing.com Nigeria
Emergent Biosolutions earnings beat by $0.22, revenue fell short of estimates - Investing.com
Emergent Biosolutions Q1 2025 slides: turnaround progress drives profitability By Investing.com - Investing.com India
Emergent BioSolutions Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Emergent BioSolutions (EBS) Updates 2025 Financial Forecast | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) Reports Strong Q1 Revenue | EBS Stoc - GuruFocus
Emergent BioSolutions Reports 656% Net Income Surge - TipRanks
Emergent Biosolutions Q1 2025 slides: turnaround progress drives profitability - Investing.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):